

Application No.: 09/980,266

### IN THE CLAIMS

Claims 1-38 (canceled)

39. (currently amended) A process for producing an injectable medicament preparation comprising: dissolving at least one ~~of a~~ therapeutically effective substance in an injectable carrier liquid, wherein the therapeutically effective substance comprises an active compound selected from the group consisting of cytostatic agent, a cytokine, an immunosuppressive agent, a virostatic agent, an antirheumatic agent, an analgesic, an antiinflammatory agent, an antibiotic, an antimycotic ~~antimicotic~~ agent, a signal transduction inhibitor, an angiogenesis inhibitor or a protease inhibitor and at least one covalently protein-binding molecular residue selected from the group consisting of maleimide, haloacetamide, haloacetate, pyridylthio, N-hydroxysuccinimide ester, isothiocyanate, disulphide, vinylcarbonyl, aziridine and acetylene, ~~acetylene~~ which are linked by a spacer comprising an organic molecular residue, which contains at least one aliphatic carbon chain, or an aliphatic carbon ring having 1-12 carbon atoms, some of which can be replaced with oxygen, or at least one aromatic moiety, in which the spacer, or the bond between the active compound and the spacer, can be cleaved hydrolytically or enzymatically in the body of a subject in a pH-dependent manner.

40. (previously presented) The process according to claim 39, wherein the spacer, or the bond between the active compound and the spacer, can be cleaved in the body of the subject, with the release of the active compound or of a derivative of the active compound.

41. (previously presented) The process according to claim 39, wherein the active compound is doxorubicin.

42. (previously presented) The process according to claim 39, wherein the active compound is selected from the group consisting of anthracyclines, nitrogen mustard derivatives, alkylating agents, purine or pyrimidine antagonists, folic acid antagonists, taxanes, camptothecins, podophyllotoxin derivatives, vinca alkaloids, calicheamicins, maytansinoids or cis-configured platinum (II) complexes.

Application No.: 09/980,266

43. (currently amended) The process according to claim 39, wherein said covalently protein-binding molecular residue ~~peptide-binding molecule~~ is phenylacetylhydrazone.
44. (currently amended) The process according to claim 39, wherein said covalently protein-binding molecular residue ~~the protein-binding molecule~~ is a maleimide.
45. (previously presented) The process according to claim 41, wherein the spacer is phenylacetylhydrazone.
46. (previously presented) The process according to claim 45, wherein said protein-binding molecular residue is maleimide.
47. (previously presented) The process according to claim 39, further comprising a carrier molecule.
48. (previously presented) The process according to claim 47, wherein the carrier molecule and the therapeutically or diagnostically effective substance are brought into contact ex vivo.
- 49-57 (canceled)